Kailera Therapeutics has filed for an IPO, ​hoping to whet investor appetites with its pipeline of drug candidates for weight loss.

Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s

Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.

One of biotech’s best-funded startups plans to go public, as it seeks to take its obesity portfolio into a market crowded by Eli Lilly, Novo

Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.